Evidence map›Paper›PMID 28439420›Full record

ArticleCerebellum & ataxias2017

An unusual cause of fatal rapid-onset ataxia plus syndrome.

Ivan Kmezic, Jan Weinberg, Dan Hauzenberger, Farouk Hashim, Evangelia Kollia, Monika Klimkowska, Inger Nennesmo, Martin Paucar

Abstract readCase Reports
In one paragraph

Article in Cerebellum & ataxias, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ivan KmezicDepartment of Neurology, Karolinska University Hospital, 141 86 Stockholm, Sweden.ORCID 0000-0001-8764-1940
Jan WeinbergDepartment of Neurology, Karolinska University Hospital, 141 86 Stockholm, Sweden.
Dan HauzenbergerDepartment of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden.
Farouk HashimDepartment of Radiology, Karolinska University Hospital, Stockholm, Sweden.
Evangelia KolliaDepartment of Radiology, Karolinska University Hospital, Stockholm, Sweden.
Monika KlimkowskaDepartment of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
Inger NennesmoDepartment of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
Martin PaucarDepartment of Neurology, Karolinska University Hospital, 141 86 Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgressive multifocal leukoencephalopathy (PML) is a demyelinating disorder of the central nervous system caused by reactivation of the JC-virus and is in most cases associated with underlying immunosuppression. Acquired immune deficiency syndrome (AIDS) and hematological malignancies are well-known predisposing factors for PML. However, in the past ten years, various pharmacological agents have been associated with increased risk of PML. Based on the phenomenology PML can be divided into the cerebral form and the rare cerebellar form. CASE PRESENTATION: Here we describe a man affected by polycythemia vera (PCV) that was treated with hydroxyurea (HU) and developed PML. The initially PML presentation included ataxia as one of the main features. Brain MRI displayed widespread supratentorial and infratentorial lesions. Immunological analysis revealed absence of reactivity to a wide range of antigens. The course of disease was rapidly progressive with fatal outcome - autopsy ruled out leukemic transformation.

conclusionThe occurrence of PML in PCV patients is very rare and has been reported only once. Movement disorders, such as ataxia, are also less frequent. In the present case the PML was likely multifactorial.

Indexed as

AtaxiaFASCIA analysisHydroxyureaJC-virusPMLPolycythemia vera

Identifiers

PMID28439420
PMCPMC5399832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.